Novavax to Participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference

GAITHERSBURG, Md., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference.

Conference details are as follows:

Date: Tuesday, December 15, 2015
Forum: One-on-one meetings
Location: The Langham Boston, Boston, MA

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

[e-mail]
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

[e-mail]
[e-mail]
212-845-4271

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1972002